Genotypic analysis of drug-resistant tuberculosis in Ghana: Insights into pre-XDR and XDR-TB
- PMID: 40392805
- PMCID: PMC12091752
- DOI: 10.1371/journal.pone.0323527
Genotypic analysis of drug-resistant tuberculosis in Ghana: Insights into pre-XDR and XDR-TB
Abstract
Background: The emergence of Extensively Drug Resistant (XDR) and Pre-extensively drug resistant (Pre-XDR) tuberculosis (TB) threatens the management of multidrug-resistant tuberculosis (MDR) patients and impacts negatively on TB control programs, especially in developing countries like Ghana. The first case of XDR-TB in Ghana was reported in 2018. There is however inadequate data on the burden of XDR-TB and pre-XDR-TB and their associated resistant mutations in Ghana. The study sought to provide baseline data on the burden of pre-XDR-TB and XDR-TB among MDR TB cases in Ghana. It also determined the mutations responsible for pre-XDR/ XDR-TB, for clinical and programmatic management of pre-XDR/ XDR-TB in Ghana.
Methods: One hundred and seventy-one (171) archived clinical MDR isolates obtained from TB patients across Ghana between January 2016 and December 2020 were retrieved. The isolates were retested to confirm their phenotypic and genotypic susceptibility to the first and second-line anti-TB drugs using the BACTEC MGIT system and Genotype MTBDRplus, MTBDRsl, line probe assays respectively.
Results: Most of the 171 isolates came from 7 regions; the highest (39.5%) from Eastern, followed by Greater Accra region (19.8%). Most of the isolates were from male TB patients (78.9%). Of the 171 archived isolates, 81 (47.4%) were confirmed to be MDR, 6 (7.4%) were Pre-XDR-TB but no XDR-TB was detected. The katG S315T1 (33, 73.3%) and rpoB S531L (31, 42.5%) were the predominant mutations observed among isoniazid and rifampicin resistant isolates respectively. Many of the mutations and amino acid changes that caused pre-XDR-TB were gyrAWT3 + gyrAMUT3A and gyrAMUT3A (D94A) (50%) for fluoroquinolone. The other detected mutations with their amino acid changes were gyrA MUT1 (A90V), gyrAWT3 + gyrA MUT3C (D94G) and gyrA MUT2 (S91P) (16.7%) for fluoroquinolones and rrWT2 (position 1484) (33.3%) and rrs MUT2 (G1484T) (16.7%) for aminoglycosides.
Conclusion: The predominant mutations associated with pre-XDR-TB were D94A and C1402T for fluoroquinolone and aminoglycosides resistance respectively. The proportion of pre-XDR-TB among MDR-TB patients in Ghana was 7.4%; however, no XDR-TB was detected. A sustained surveillance of pre-XDR-TB and XDR-TB is recommended.
Copyright: © 2025 Yirenkyi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.PLoS One. 2024 May 6;19(5):e0301210. doi: 10.1371/journal.pone.0301210. eCollection 2024. PLoS One. 2024. PMID: 38709710 Free PMC article.
-
Genotypic and phenotypic drug resistance patterns of Mycobacterium tuberculosis isolated from presumptive pulmonary tuberculosis patients in Ethiopia: A multicenter study.PLoS One. 2024 May 16;19(5):e0303460. doi: 10.1371/journal.pone.0303460. eCollection 2024. PLoS One. 2024. PMID: 38753615 Free PMC article.
-
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.BMC Infect Dis. 2018 Feb 27;18(1):98. doi: 10.1186/s12879-018-3009-9. BMC Infect Dis. 2018. PMID: 29486710 Free PMC article.
-
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.Int J Infect Dis. 2023 Jul;132:50-63. doi: 10.1016/j.ijid.2023.04.392. Epub 2023 Apr 16. Int J Infect Dis. 2023. PMID: 37072053 Free PMC article.
-
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.Curr Clin Pharmacol. 2010 May;5(2):96-114. doi: 10.2174/157488410791110797. Curr Clin Pharmacol. 2010. PMID: 20156156 Free PMC article. Review.
References
-
- 2024 global tuberculosis report. World Health Organization; 2024.
-
- Acheampong D, Opoku R, Boye A, Agyirifo D, Dadzie I, Barnie P, et al.. Diagnosis and treatment outcome of smear positive pulmonary tuberculosis: retrospective study in Kpando Municipal, Ghana. J Adv Med Med Res. 2018;25(9):1–11. doi: 10.9734/jammr/2018/40156 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources